Children with MS - 82% lower relapse rate with Gilenya
Posted: Mon Oct 30, 2017 7:55 am
Children and adolescents with MS experience an 82% lower relapse rate with Gilenya vs. interferon beta-1a #ECTRIMS
Pharmaceutical company Novartis has released the full results of a phase III Paradigms study investigating the safety and efficiency of Gilenya (fingolimod) vs. interferon beta-1a in children and adolescents aged 10-17 with MS...Read more - http://www.ms-uk.org/children-and-adole ... 1a-ectrims
Pharmaceutical company Novartis has released the full results of a phase III Paradigms study investigating the safety and efficiency of Gilenya (fingolimod) vs. interferon beta-1a in children and adolescents aged 10-17 with MS...Read more - http://www.ms-uk.org/children-and-adole ... 1a-ectrims